Ajaypal Singh to Middle Aged
This is a "connection" page, showing publications Ajaypal Singh has written about Middle Aged.
Connection Strength
1.886
-
Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008 Sep; 74(6):782-90.
Score: 0.125
-
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602.
Score: 0.082
-
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022 04 25; 37(5):960-972.
Score: 0.082
-
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2325-2335.
Score: 0.079
-
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2313-2324.
Score: 0.079
-
Occupational risk factors for chronic kidney disease in Andhra Pradesh: 'Uddanam Nephropathy'. Ren Fail. 2020 Nov; 42(1):1032-1041.
Score: 0.074
-
Necrotizing fasciitis of the lower extremity: imaging pearls and pitfalls. Br J Radiol. 2018 Jul; 91(1088):20180093.
Score: 0.062
-
Head and neck injuries from the Boston Marathon bombing at four hospitals. Emerg Radiol. 2015 Oct; 22(5):527-32.
Score: 0.050
-
Radiologic features of injuries from the Boston Marathon bombing at three hospitals. AJR Am J Roentgenol. 2014 Aug; 203(2):235-9.
Score: 0.048
-
Burden and predictors of hypertension in India: results of SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol. 2014 Mar 06; 15:42.
Score: 0.046
-
Prevalence of vitamin D deficiency in Saudi adults. Saudi Med J. 2013 Aug; 34(8):814-8.
Score: 0.045
-
Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol. 2013 May 28; 14:114.
Score: 0.044
-
Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents. Clin Appl Thromb Hemost. 2012 Sep; 18(5):453-61.
Score: 0.041
-
Epidemiology of chronic kidney disease in the Kingdom of Saudi Arabia (SEEK-Saudi investigators) - a pilot study. Saudi J Kidney Dis Transpl. 2010 Nov; 21(6):1066-72.
Score: 0.037
-
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010 Feb; 77(3):239-46.
Score: 0.034
-
Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis. 2009 May; 53(5):751-9.
Score: 0.033
-
Core biopsy with curved needle technique. AJR Am J Roentgenol. 2008 Dec; 191(6):1745-50.
Score: 0.032
-
Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. Nephron Clin Pract. 2008; 110(4):c244-50.
Score: 0.032
-
Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int. 2008 Dec; 74(12):1588-95.
Score: 0.032
-
Emergency MRI of acute pelvic pain: MR protocol with no oral contrast. Emerg Radiol. 2009 Mar; 16(2):133-41.
Score: 0.031
-
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008 Sep; 74(6):791-8.
Score: 0.031
-
Neoplastic iliopsoas masses in oncology patients: CT findings. Abdom Imaging. 2008 Jul-Aug; 33(4):493-7.
Score: 0.031
-
Acute phosphate nephropathy. Kidney Int. 2009 May; 75(9):987-91.
Score: 0.031
-
Pure red cell aplasia due to follow-on epoetin. Kidney Int. 2008 Dec; 74(12):1617-22.
Score: 0.031
-
Acute coronary syndrome in ESRD patients. Kidney Int. 2009 Mar; 75(5):558-62.
Score: 0.031
-
Dropped appendicolith: CT findings and implications for management. AJR Am J Roentgenol. 2008 Mar; 190(3):707-11.
Score: 0.031
-
Prevention of intravenous contrast-induced nephropathy in hospital inpatients. Crit Pathw Cardiol. 2008 Mar; 7(1):1-4.
Score: 0.031
-
The nephrology quiz and questionnaire: 2006. Clin J Am Soc Nephrol. 2007 Nov; 2(6):1375-88.
Score: 0.030
-
Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocr Pract. 2007 May-Jun; 13(3):251-9.
Score: 0.029
-
Imaging-guided catheter drainage of abdominal collections with fistulous pancreaticobiliary communication. AJR Am J Roentgenol. 2006 Dec; 187(6):1591-6.
Score: 0.028
-
Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16; 355(20):2085-98.
Score: 0.028
-
Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procurement and Transplantation Network database. Transplantation. 2006 Sep 15; 82(5):612-8.
Score: 0.028
-
Acute epiploic appendagitis in hernia sac: CT appearance. Emerg Radiol. 2005 Jun; 11(4):226-7.
Score: 0.025
-
New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences? Am J Kidney Dis. 2004 Dec; 44(6):1050-9.
Score: 0.024
-
CT appearance of acute appendagitis. AJR Am J Roentgenol. 2004 Nov; 183(5):1303-7.
Score: 0.024
-
Omental infarct: an unusual CT appearance after superior mesenteric artery occlusion. Emerg Radiol. 2004 Apr; 10(5):276-8.
Score: 0.023
-
Imaging of inflammatory bowel disease: CT and MR. Dig Dis. 2004; 22(1):56-62.
Score: 0.023
-
A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol. 2003 Oct; 14(10):2573-80.
Score: 0.023
-
Accuracy and timeliness of an abbreviated emergency department MRCP protocol for choledocholithiasis. Emerg Radiol. 2019 Aug; 26(4):427-432.
Score: 0.017
-
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019 05; 21(5):1199-1208.
Score: 0.016
-
The Prevalence, Clinical Spectrum and the Long Term Outcome of ST-segment Elevation Myocardial Infarction in Young - A Prospective Observational Study. Cardiovasc Revasc Med. 2019 05; 20(5):387-391.
Score: 0.016
-
The added value of cross-sectional imaging in the detection of additional radiographically occult fractures in the setting of a Chopart fracture. Emerg Radiol. 2018 Oct; 25(5):513-520.
Score: 0.016
-
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. Am J Nephrol. 2017; 46(6):488-497.
Score: 0.015
-
BP in Dialysis: Results of a Pilot Study. J Am Soc Nephrol. 2018 01; 29(1):307-316.
Score: 0.015
-
A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. Am J Nephrol. 2017; 46(5):364-370.
Score: 0.015
-
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type?2 Diabetic Patients With CKD. Am J Kidney Dis. 2017 Oct; 70(4):522-531.
Score: 0.015
-
Ferric pyrophosphate citrate (Triferic?) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant. 2015 Dec; 30(12):2019-26.
Score: 0.013
-
Cause of Death in Patients With Diabetic CKD Enrolled in the?Trial to Reduce Cardiovascular Events With Aranesp Therapy?(TREAT). Am J Kidney Dis. 2015 Sep; 66(3):429-40.
Score: 0.013
-
Cognitive function and all-cause mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2015 Feb; 65(2):303-11.
Score: 0.012
-
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6):549-58.
Score: 0.011
-
Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology. 2013 Jan 29; 80(5):471-80.
Score: 0.011
-
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis. 2013 Feb; 61(2):238-46.
Score: 0.011
-
Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis. 2012 Sep; 60(3):390-401.
Score: 0.010
-
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.
Score: 0.010
-
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16; 363(12):1146-55.
Score: 0.009
-
Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant. 2010 May; 25(5):1567-75.
Score: 0.009
-
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19; 361(21):2019-32.
Score: 0.009
-
Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis. 2009 Sep; 54(3):498-510.
Score: 0.008
-
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009 Jul; 54(1):59-69.
Score: 0.008
-
Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008 Feb; 19(2):372-9.
Score: 0.008
-
Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol. 2007 Dec; 18(12):3184-91.
Score: 0.007
-
Tc-99m ciprofloxacin scans for detection of tubercular bone infection. Clin Nucl Med. 2007 May; 32(5):367-70.
Score: 0.007
-
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007 Mar; 18(3):975-84.
Score: 0.007
-
Associations between demographic factors and provider structures on cost and length of stay for hemodialysis patients with vascular access failure. Clin J Am Soc Nephrol. 2006 May; 1(3):455-61.
Score: 0.007